Nonpenetrating glaucoma surgery cannot achieve lower target IOP

Article

Nonpenetrating glaucoma surgery has little potential to reduce intraocular pressure (IOP) values, according to a study published in the March issue of the Journal of Ophthalmology.

Nonpenetrating glaucoma surgery has little potential to reduce intraocular pressure (IOP) values, according to a study published in the March issue of the Journal of Glaucoma.

Ahmet Hondur, MD of Dinar State Hospital, Turkey and colleagues assessed the impact of nonpenetrating surgery on IOP by reviewing studies on nonpenetrating glaucoma surgery, deep sclerectomy (DS) and viscocanalostomy (VC) (excluding those reporting on combined glaucoma and cataract surgery) from the past five years.

Following primary DS, DS with implant, DS with antimetabolite, primary VC and VC with implant or antimetabolite, cases achieving IOP of ≤21 mmHg were 48.6%, 68.7%, 67.1%, 51.1% and 36.8%, respectively. The research team determined effectiveness in terms of target IOP achievement. For lower set IOP targets, DS and VC success rates were 35 – 86% and 10 – 67%, respectively.

Based on these data, the team concluded that the potential of nonpenetrating surgery to achieve lower target IOPs is low, although this type of surgery can reduce IOP into the high teens.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.